Background
Phase III, double-blind, placebo-controlled RCT. 267 patients with R/R MCL after 1–5 prior lines (including anti-CD20). Venetoclax (BCL-2 inhibitor) and ibrutinib (BTK inhibitor) have synergistic mechanisms in MCL. SYMPATICO was the first phase III RCT of a BTK + BCL-2 combination in MCL.
Interventions and follow up
Arm A: Ibrutinib 560mg PO daily + venetoclax (5-week ramp-up from 20mg to 400mg PO daily) — continuous until progression; tumor lysis syndrome prophylaxis required during ramp-up
Arm B: Ibrutinib 560mg PO daily + placebo
Primary endpoint: Progression-free survival (investigator-assessed)
Median follow-up: 50.9 months
Arm B: Ibrutinib 560mg PO daily + placebo
Primary endpoint: Progression-free survival (investigator-assessed)
Median follow-up: 50.9 months
Results
Median PFS: 31.9 vs 22.1 months, HR 0.65, 95% CI 0.47–0.88, P=.0052
3-year PFS: 46.1% vs 37.2%
Median OS: 44.9 vs 38.6 months, HR 0.85, 95% CI 0.59–1.22, P=.37 — not significant
ORR: 82.2% vs 74.1%; CR 54.8% vs 43.2%
MRD negativity: 45.0% vs 18.4%
3-year PFS: 46.1% vs 37.2%
Median OS: 44.9 vs 38.6 months, HR 0.85, 95% CI 0.59–1.22, P=.37 — not significant
ORR: 82.2% vs 74.1%; CR 54.8% vs 43.2%
MRD negativity: 45.0% vs 18.4%
Adverse events
Hematologic/TLS (ibrutinib+venetoclax vs ibrutinib): Grade ≥3 AEs 80.0% vs 75.6%; grade ≥3 neutropenia 30.6% vs 17.3%; TLS any grade 4.5% vs 0.7%.
Cardiac/bleeding/infection: Atrial fibrillation 17.2% vs 14.0%; bleeding any grade 43.3% vs 42.4%; grade ≥3 infection 22.4% vs 19.8%.
Cardiac/bleeding/infection: Atrial fibrillation 17.2% vs 14.0%; bleeding any grade 43.3% vs 42.4%; grade ≥3 infection 22.4% vs 19.8%.
Conclusions
Ibrutinib + venetoclax significantly improved PFS versus ibrutinib alone in R/R MCL (HR 0.65, median PFS 31.9 vs 22.1 months), with markedly higher MRD negativity (45% vs 18%). OS did not reach statistical significance, likely reflecting effective post-progression salvage.
Key Limitations
OS benefit not demonstrated — likely reflects salvage options post-progression. TLS risk requires hospitalization and a ramp-up protocol, adding logistical complexity. Long-term efficacy of ibrutinib + venetoclax versus other approaches in an era of CAR-T and bispecifics needs further evaluation. Venetoclax resistance after BTK inhibitor exposure may limit subsequent therapy options.
Clinical Context
SYMPATICO is the first phase III evidence for a chemotherapy-free BTK + BCL-2 doublet in MCL, offering an all-oral, non-chemotherapy option, particularly for patients intolerant of chemoimmunotherapy. Availability is affected by ibrutinib's voluntary MCL withdrawal in some markets, where next-generation BTK inhibitors (acalabrutinib, zanubrutinib, pirtobrutinib) are now favored. ASCO/ESMO guidance supports BTK inhibitor-based regimens in R/R MCL.